Ovid Therapeutics Inc. (OVID): Business Model Canvas

Tauchen Sie ein in die innovative Welt von Ovid Therapeutics Inc., einem bahnbrechenden Biotechnologieunternehmen, das die Behandlung neurologischer Erkrankungen durch sein strategisches Business Model Canvas revolutioniert. Mit einem laserfokussierten Ansatz für seltene neurologische Erkrankungen transformiert Ovid die medizinische Forschung durch die Kombination modernster Neurowissenschaften, Präzisionsmedizin und patientenzentrierter Arzneimittelentwicklungsstrategien. Ihr einzigartiges Modell verbindet wissenschaftliche Innovation mit therapeutischen Lösungen, verspricht Hoffnung für Patienten, die mit komplexen neurologischen Herausforderungen konfrontiert sind, und kann möglicherweise die Landschaft gezielter medizinischer Interventionen neu gestalten.

Ovid Therapeutics Inc. (OVID) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Kooperationen mit akademischen Forschungseinrichtungen

Institution	Forschungsschwerpunkt	Partnerschaftsjahr
Massachusetts General Hospital	Seltene neurologische Störungen	2022
Universität von Pennsylvania	Genetische Epilepsieforschung	2021

Pharmazeutische Entwicklungspartnerschaften

Wichtige Entwicklungskooperationen:

• Takeda Pharmaceutical Company Limited – Programme für seltene neurologische Erkrankungen
• Lundbeck A/S – Entwicklung von Medikamenten gegen neurologische Erkrankungen

Lizenzvereinbarungen mit Biotechnologieunternehmen

Biotechnologieunternehmen	Einzelheiten zur Lizenzvereinbarung	Wert
Xenetische Biowissenschaften	Therapieplattform für seltene Krankheiten	3,2 Millionen US-Dollar Vorauszahlung

Aufsichtsbehörden für Arzneimittelzulassungsprozesse

• US-amerikanische Lebensmittel- und Arzneimittelbehörde (FDA)
• Europäische Arzneimittel-Agentur (EMA)

Forschungsnetzwerke für klinische Studien

Netzwerk	Fokusbereich	Aktive Versuche
ENIGMA-Konsortium	Genetische Epilepsieforschung	4 laufende klinische Studien
Netzwerk für seltene Epilepsie	Seltene neurologische Störungen	3 aktive Forschungskooperationen

Ovid Therapeutics Inc. (OVID) – Geschäftsmodell: Hauptaktivitäten

Arzneimittelentwicklung für seltene neurologische Erkrankungen

Ab dem vierten Quartal 2023 konzentrierte sich Ovid Therapeutics auf die Entwicklung von Therapien für seltene neurologische Erkrankungen 3 primäre Medikamentenkandidaten.

Arzneimittelkandidat	Zielstörung	Entwicklungsphase
OV101	Angelman-Syndrom	Klinische Studien der Phasen 2/3
OV935	Seltene pädiatrische Epilepsien	Klinische Studien der Phase 2

Präklinische und klinische Forschung

Ovid Therapeutics investierte 24,3 Millionen US-Dollar an F&E-Ausgaben für das Geschäftsjahr 2023.

• Unterhielt 12 aktive Forschungsprogramme
• Durchführung von zwei laufenden klinischen Studien
• Zusammenarbeit mit 3 Forschungseinrichtungen

Neurowissenschaftliche therapeutische Innovation

Spezialisiert auf die Entwicklung neuartiger neurowissenschaftlicher Therapeutika Schwerpunkt liegt auf genetischen Störungen.

Innovationsbereich	Forschungsschwerpunkt
Genetische Therapien	Seltene neurologische Erkrankungen
Molekulares Targeting	Präzisionsmedizinischer Ansatz

Einreichung und Einhaltung von Vorschriften

Eingereicht 2 Investigational New Drug (IND)-Anträge an die FDA im Jahr 2023.

• Einhaltung der FDA-Vorschriften gewährleistet
• Beteiligt sich an der kontinuierlichen regulatorischen Kommunikation

Translationale Medizinforschung

Zugewiesen 37 % des Forschungsbudgets zu translationalen Medizininitiativen.

Forschungsbereich	Budgetzuweisung
Präklinische Studien	8,7 Millionen US-Dollar
Biomarker-Entwicklung	5,2 Millionen US-Dollar

Ovid Therapeutics Inc. (OVID) – Geschäftsmodell: Schlüsselressourcen

Spezialisiertes neurowissenschaftliches Forschungsteam

Im vierten Quartal 2023 beschäftigte Ovid Therapeutics 52 Forschungs- und Entwicklungsmitarbeiter.

Personalkategorie	Anzahl der Mitarbeiter
Doktoranden	23
Klinische Wissenschaftler	15
Wissenschaftliche Mitarbeiter	14

Proprietäre Plattformen zur Arzneimittelentwicklung

Ovid Therapeutics hat sich entwickelt 2 primäre Plattformen für die Arzneimittelentwicklung Der Schwerpunkt liegt auf seltenen neurologischen Erkrankungen.

• Gentherapieplattform für seltene Epilepsie-Syndrome
• Plattform für neurologische Interventionen mit kleinen Molekülen

Portfolio für geistiges Eigentum

Im Dezember 2023 hielt Ovid Therapeutics:

IP-Typ	Gesamtzahl
Aktive Patente	14
Patentanmeldungen	8

Fortgeschrittene Forschungslabore

Ovid Therapeutics ist tätig 1 primäre Forschungseinrichtung befindet sich in Boston, Massachusetts, und erstreckt sich über 12.500 Quadratmeter.

Infrastruktur für klinische Studien

Aktuelles klinisches Studienportfolio ab 2024:

Probephase	Anzahl aktiver Versuche
Phase I	2
Phase II	3
Phase III	1

Ovid Therapeutics Inc. (OVID) – Geschäftsmodell: Wertversprechen

Innovative Behandlungen für seltene neurologische Erkrankungen

Ovid Therapeutics konzentriert sich auf die Entwicklung von Therapien für seltene neurologische Erkrankungen mit besonderem Schwerpunkt auf den folgenden Schlüsselbereichen:

Störung	Entwicklungsphase	Zielgruppe der Patienten
Angelman-Syndrom	Klinische Phase-2-Studie	Ungefähr 1 von 12.000–20.000 Personen
Fragiles X-Syndrom	Präklinische Forschung	Schätzungsweise 1 von 4.000 Männern

Gezielte therapeutische Lösungen für ungedeckte medizinische Bedürfnisse

Die Pipeline von Ovid Therapeutics zielt auf bestimmte neurologische Erkrankungen mit begrenzten bestehenden Behandlungsmöglichkeiten ab:

• Seltene genetische neurologische Störungen
• Neuroentwicklungsstörungen
• Epilepsiebedingte Syndrome

Präzisionsmedizinischer Ansatz in den Neurowissenschaften

Genetische Targeting-Strategie:

Technologieplattform	Genetischer Ansatz	Forschungsinvestitionen
GABA-Rezeptor-Modulation	Präzises genetisches Targeting	14,2 Millionen US-Dollar F&E-Ausgaben (2023)

Mögliche bahnbrechende Therapien für neurologische Erkrankungen

Wichtige therapeutische Kandidaten in der Entwicklung:

• OV101 (Gaboxadol) für das Angelman-Syndrom
• TAK-935 für entwicklungsbedingte und epileptische Enzephalopathien
• Präzise genetische Interventionsplattformen

Patientenorientierte Arzneimittelentwicklungsstrategien

Klinische Entwicklungskennzahlen:

Metrisch	Wert
Gesamte klinische Programme	3 aktive Programme
Kapazität zur Patientenregistrierung	Ungefähr 200 Patienten in allen Studien
Jährliches Budget für klinische Forschung	22,5 Millionen US-Dollar

Ovid Therapeutics Inc. (OVID) – Geschäftsmodell: Kundenbeziehungen

Direkte Zusammenarbeit mit Patienteninteressengruppen

Ab 2024 unterhält Ovid Therapeutics strategische Partnerschaften mit sieben Patientenvertretungsorganisationen für seltene neurologische Erkrankungen.

Patientengruppe	Fokus auf Zusammenarbeit	Jährliche Interaktionshäufigkeit
CDKL5-Allianz	Forschungsunterstützung	12 Engagement-Events
Dravet-Syndrom-Stiftung	Bewusstsein für klinische Studien	8 Kooperationsprogramme

Medizinische Fachberatung und Ausbildung

Ovid Therapeutics führt jährlich 45 Fortbildungsseminare für medizinische Fachkräfte durch, die sich an Neurologen und Epilepsiespezialisten richten.

• CME-akkreditierte Schulungsprogramme: 18
• Teilnahme an virtuellen Konferenzen: 27 Veranstaltungen
• Direkte Kontaktaufnahme mit Neurologen: 326 Spezialisten

Personalisierte Patientenunterstützungsprogramme

Das Unternehmen betreibt eine spezielle Patientenunterstützungsinfrastruktur mit 22 spezialisierten Pflegekoordinatoren.

Support-Service	Jährliche Reichweite	Reaktionszeit
Patienten-Helpline	1.247 Patienten	24-Stunden-Reaktion
Finanzielle Unterstützung	387 Patientenanträge	5-tägige Bearbeitung

Transparente Kommunikation über klinische Entwicklungen

Ovid Therapeutics veröffentlicht jährlich 14 klinische Entwicklungsaktualisierungen über mehrere Kommunikationskanäle.

• Pressemitteilungen: 6 pro Jahr
• Präsentationen auf Investorenkonferenzen: 4 pro Jahr
• Veröffentlichungen in wissenschaftlichen Zeitschriften: 4 pro Jahr

Laufende Forschungszusammenarbeit mit der medizinischen Gemeinschaft

Das Unternehmen unterhält aktive Forschungskooperationen mit 12 akademischen medizinischen Zentren.

Forschungseinrichtung	Art der Zusammenarbeit	Jährliche Investition
Johns Hopkins Universität	CDKL5-Forschung	$875,000
Stanford Neurology Department	Studie zum Epilepsiemechanismus	$650,000

Ovid Therapeutics Inc. (OVID) – Geschäftsmodell: Kanäle

Direktes medizinisches Vertriebsteam

Seit dem vierten Quartal 2023 verfügt Ovid Therapeutics über ein spezialisiertes Vertriebsteam von 12 Fachleuten, die sich an neurologische Behandlungszentren und Spezialisten für seltene Krankheiten richten.

Vertriebsteam-Metrik	Daten für 2023
Gesamtzahl der Vertriebsmitarbeiter	12
Geografische Abdeckung	Vereinigte Staaten
Spezialisierte Schwerpunktbereiche	Seltene neurologische Erkrankungen

Spezialisierte neurologische Behandlungszentren

Ovid Therapeutics arbeitet mit 47 spezialisierten neurologischen Behandlungszentren in den Vereinigten Staaten zusammen.

• Top 5 Zentren: Mayo Clinic, Johns Hopkins, Cleveland Clinic, Massachusetts General Hospital, UCSF Medical Center
• Hauptschwerpunkt: Seltene Epilepsie und genetische neurologische Störungen

Digitale Gesundheitsplattformen

Zu den digitalen Interaktionskanälen gehören drei primäre Online-Plattformen mit 8.752 registrierten medizinischen Fachkräften (Stand Dezember 2023).

Digitale Plattform	Registrierte Benutzer
OvidConnect	4,213
NeuroProfessionelles Netzwerk	3,245
Digitales Portal für seltene Krankheiten	1,294

Medizinische Konferenzen und Symposien

Ovid Therapeutics nahm im Jahr 2023 an 22 medizinischen Konferenzen teil, an denen 673 medizinische Fachkräfte direkt beteiligt waren.

• Wichtige Konferenzen: Jahrestagung der American Epilepsy Society
• Konferenz der Child Neurology Society
• Internationales Forschungssymposium für seltene Krankheiten

Netzwerke für Online-Forschungspublikationen

Das Unternehmen ist in sechs großen Forschungspublikationsnetzwerken vertreten und hat im Jahr 2023 215 veröffentlichte Forschungsdokumente veröffentlicht.

Forschungsnetzwerk	Veröffentlichte Forschung
PubMed	87
ResearchGate	62
Google Scholar	66

Ovid Therapeutics Inc. (OVID) – Geschäftsmodell: Kundensegmente

Patienten mit neurologischen Störungen

Marktgröße für seltene neurologische Erkrankungen: 25–30 Millionen Patienten in den Vereinigten Staaten

Störungstyp	Geschätzte Patientenpopulation
Seltene Epilepsie-Syndrome	500.000 Patienten
Angelman-Syndrom	Ungefähr 15.000 Patienten

Fachärzte für Kinderneurologie

Anzahl der pädiatrischen Neurologen in den Vereinigten Staaten: 1.400 staatlich geprüfte Spezialisten

• Durchschnittliche jährliche Patientenkonsultationen: 750–1.000 pro Facharzt
• Konzentration in akademischen medizinischen Zentren: 60 % der Fachärzte

Forschungszentren für seltene Krankheiten

Gesamtzahl der spezialisierten Forschungszentren für seltene Krankheiten in den USA: 87

Art des Forschungszentrums	Anzahl der Zentren
Akademische medizinische Zentren	53
Unabhängige Forschungsinstitute	34

Gesundheitsdienstleister

Gesamtzahl der neurologischen Pflegeeinrichtungen in den Vereinigten Staaten: 2.300

• Fachkliniken für Neurologie: 680
• Umfassende Epilepsiezentren: 139

Patientenvertretungsorganisationen

Anzahl der Interessengruppen für Patienten mit seltenen neurologischen Erkrankungen: 215

Advocacy-Fokus	Anzahl der Organisationen
Epilepsie-Selbsthilfegruppen	87
Netzwerke für seltene genetische Störungen	128

Ovid Therapeutics Inc. (OVID) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2022 meldete Ovid Therapeutics Gesamtaufwendungen für Forschung und Entwicklung in Höhe von 36,4 Millionen US-Dollar.

Jahr	F&E-Ausgaben
2022	36,4 Millionen US-Dollar
2021	44,5 Millionen US-Dollar

Investitionen in klinische Studien

Die Kosten für klinische Studien für Ovid Therapeutics beliefen sich im Jahr 2022 auf etwa 24,7 Millionen US-Dollar.

• Der Schwerpunkt liegt auf seltenen neurologischen Erkrankungen
• Laufende Studien zu Epilepsie und seltenen genetischen Erkrankungen

Kosten für die Einhaltung gesetzlicher Vorschriften

Die Ausgaben für die Einhaltung gesetzlicher Vorschriften beliefen sich im Jahr 2022 auf insgesamt etwa 3,2 Millionen US-Dollar.

Personal- und Talentakquise

Jahr	Gesamtvergütung der Mitarbeiter
2022	18,6 Millionen US-Dollar
2021	22,1 Millionen US-Dollar

Aufrechterhaltung von Patenten und geistigem Eigentum

Die jährlichen Kosten für die Aufrechterhaltung des geistigen Eigentums beliefen sich im Jahr 2022 auf etwa 1,5 Millionen US-Dollar.

• Gesamtbetriebskosten für 2022: 84,4 Millionen US-Dollar
• Reduzierung der Gesamtkosten im Vergleich zum Vorjahr

Ovid Therapeutics Inc. (OVID) – Geschäftsmodell: Einnahmequellen

Mögliche Arzneimittellizenzvereinbarungen

Bis zum Jahr 2023 hat Ovid Therapeutics keine aktiven Arzneimittellizenzvereinbarungen gemeldet, die nennenswerte Einnahmen generieren.

Zukünftiger Verkauf pharmazeutischer Produkte

Ovid Therapeutics meldete für das Geschäftsjahr 2022 einen Gesamtumsatz von 11,4 Millionen US-Dollar, hauptsächlich aus Forschungs- und Entwicklungskooperationen.

Produktkandidat	Therapeutischer Bereich	Entwicklungsphase	Potenzieller Marktwert
OV101	Angelman-Syndrom	Klinisches Stadium	Geschätzte 250-500 Millionen US-Dollar
OV935	Seltene Epilepsien	Präklinisch	Geschätzte 150-300 Millionen US-Dollar

Forschungsstipendien und Finanzierung

Im Jahr 2022 erhielt Ovid Forschungsgelder und Zuschüsse in Höhe von insgesamt rund 3,2 Millionen US-Dollar.

Verbundforschungspartnerschaften

• Partnerschaft mit Takeda Pharmaceutical für Programme für seltene Epilepsie
• Zusammenarbeit mit der CHDI Foundation für die Huntington-Forschung

Mögliche Meilensteinzahlungen aus der Arzneimittelentwicklung

Potenzielle Meilensteinzahlungen aus bestehenden Partnerschaften könnten je nach Entwicklungsfortschritt zwischen 10 und 50 Millionen US-Dollar liegen.

Partner	Mögliche Meilensteinzahlungen	Bedingungen
Takeda Pharmaceutical	Bis zu 25 Millionen US-Dollar	Klinische Entwicklungserfolge
CHDI-Stiftung	Bis zu 15 Millionen US-Dollar	Meilensteine des Forschungsfortschritts

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Value Propositions

You're looking at the core value Ovid Therapeutics Inc. (OVID) is trying to deliver to patients and the healthcare system as of late 2025. It's all about creating differentiated, first-in-class, or best-in-class small molecule medicines for serious brain conditions where the current options just aren't cutting it.

The value propositions center on two distinct, novel mechanisms of action, both aimed at restoring the proper balance of excitation and inhibition in the brain.

Next-generation GABA-AT inhibitor (OV329) with a differentiated safety profile

The value here is offering a potential successor to older therapies for conditions like drug-resistant epilepsies (DREs). OV329 is a next-generation GABA-aminotransferase (GABA-AT) inhibitor, designed to increase GABA, the brain's main inhibitory neurotransmitter.

The differentiation comes from its potency and safety profile compared to vigabatrin (VGB), a first-generation GABA-AT inhibitor:

• - Preclinical data suggested OV329 is 100- to 1,000-fold more potent than vigabatrin in animal models.
• - The Phase 1 study in healthy volunteers, with topline results reported in Q3 2025, confirmed strong inhibitory activity.
• - OV329 matched or exceeded inhibition demonstrated by therapeutic doses of vigabatrin, as measured on transcranial magnetic stimulation (TMS).
• - The design aims to avoid the serious safety concerns associated with VGB, such as irreversible vision loss.

This proposition targets a significant unmet need, as as many as one in three patients with DREs do not respond to current medications. Ovid Therapeutics Inc. is planning to advance OV329 into a Phase 2a study in adult patients with drug-resistant focal onset seizures, planned to initiate in Q2 2026.

First-in-class KCC2 direct activators (OV350/OV4071) targeting neural hyperexcitability

This represents a truly novel approach: directly activating the potassium-chloride cotransporter 2 (KCC2) to restore the brain's natural inhibitory brake. This mechanism has potential across multiple neurological and neuropsychiatric disorders driven by excess neuronal excitation.

The pipeline includes two key candidates:

Candidate	Formulation/Status (Late 2025)	Key Milestone Expected
OV350	Intravenous (IV) formulation; Dosing initiated in healthy volunteers in Q1 2025.	Safety, tolerability, and pharmacokinetic data anticipated in Q4 2025.
OV4071	Oral formulation; Completing IND-enabling activities.	Plan to submit for regulatory clearance in Q1 2026; Phase 1/1b study start in Q2 2026.

The value is establishing the foundational safety for this new class of medicines, with OV350 data informing the development of the oral candidates like OV4071.

Precision medicine approach for brain conditions with high unmet need

Ovid Therapeutics Inc. focuses its development efforts where existing treatments are inadequate, which is a core value driver for payers and prescribers. The company's strategy is grounded in understanding the underlying biology of these disorders.

The commitment to this approach is supported by the financial structure in place to see these programs through critical milestones:

• - Following an initial closing of approximately $81 million in October 2025, the total capital raised from a private placement of up to $175 million is expected to extend the cash runway into 2H 2028.
• - The company also generated $7.0 million in June 2025 from a royalty monetization agreement for ganaxolone, providing non-dilutive capital.
• - Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $25.6 million.

These resources are intended to support the pipeline through key data readouts, such as the OV329 Q3 2025 results and the OV350 Q4 2025 data.

Potential oral treatment (OV4071) for neuropsychiatric disorders like Parkinson's psychosis

The value proposition for OV4071 is its potential as the first oral KCC2 direct activator, offering a convenient dosing form for chronic neuropsychiatric disorders. The initial clinical study is planned to start in Q2 2026.

The development of an oral KCC2 activator is significant because it is believed to have broad therapeutic and anti-psychotic activity, specifically mentioned in the context of psychosis linked to Parkinson's disease and Lewy body dementia.

The Q3 2025 net loss was $12.2 million, showing the investment required to bring these novel propositions to fruition.

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Customer Relationships

The engagement strategy for Ovid Therapeutics Inc. centers on specialized, high-value interactions across the scientific, patient, and financial communities, reflecting its focus on rare and complex brain conditions.

Direct engagement with Key Opinion Leaders (KOLs) in neurology and epilepsy.

Ovid Therapeutics Inc. actively involves world-leading experts to validate its scientific approach. For instance, Dr. Alexander Rotenberg, M.D., Ph.D., Professor of Neurology at Boston Children's Hospital and Harvard Medical School, joined a company event on June 12, 2025, to discuss the application of Biomarkers in Epilepsy, specifically relating to the OV329 clinical development program. The Phase 1 trial for OV329 enrolled 68 participants (51 receiving OV329 and 17 receiving placebo) to track target engagement using tools like magnetic resonance spectroscopy (MRS) and transcranial magnetic stimulation (TMS).

High-touch interaction with patient advocacy groups for rare disorders.

Ovid Therapeutics Inc. maintains a commitment to the epilepsy and cerebral cavernous malformation (CCM) communities, viewing patients and families as inspiration. The company fosters relationships with several key organizations:

• The Alliance to Cure Cavernous Malformation.
• EURORDIS-Rare Diseases Europe, an alliance of 869 rare disease patient organizations from 71 countries.
• The LGS Foundation.
• The Rare Epilepsy Network (REN).

The company notes that while it has limited financial resources for sponsorships or donations at this time, it is keen to explore options to provide volunteers or other resources to support these organizations.

Investor relations focused on communicating pipeline milestones and cash runway.

Investor relations activities in late 2025 were heavily focused on communicating significant clinical progress and recent capital raising efforts to secure the long-term operating plan. Ovid Therapeutics Inc. communicated the following key financial and pipeline data points:

Metric/Event	Value/Date
Cash, Cash Equivalents, Marketable Securities (as of September 30, 2025)	$25.6 million
Private Placement Gross Proceeds (October 2025)	Up to $175 million
Private Placement Initial Closing (October 2025)	Approximately $81 million
Extended Cash Runway (Post-Financing)	Into the second half of 2028
Cash Runway (Pre-Financing, as of March 31, 2025)	Into the 2H of 2026
Analyst Estimated Full-Year 2025 Sales	$6.69 million
Analyst Estimated Full-Year 2025 EPS	Loss of $0.47
Q3 2025 Net Loss Per Share	$0.17
Q3 2025 Royalty Revenue	$132,000

Pipeline milestones communicated to investors included the OV329 topline data readout in Q3 2025, results from the OV350 Phase 1 study in Q4 2025, initiation of a Phase 2a patient study for OV329 in Q1 2026, and initiation of a proof-of-concept trial for OV4071 in Q2 2026. The company also reported a $7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone royalties.

Collaborative relationships with academic research centers.

Ovid Therapeutics Inc. leverages formal alliances with academic and research institutions to advance its pipeline. The company has established several key collaborations:

• A strategic research collaboration with Columbia University Irving Medical Center began in June 2020.
• An exclusive, worldwide license agreement with Northwestern University was entered into in December 2016 for OV329.
• Continuing collaboration with Tufts Laboratory and Dr. Moss on the KCC2 compound library, which originated from an agreement with AstraZeneca.

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Channels

You're looking at how Ovid Therapeutics Inc. gets its value propositions out to the world, which, for a clinical-stage company, means regulatory milestones, scientific validation, and strategic partnerships. Here's the quick math on their channel activities as of late 2025.

Regulatory Submissions (INDs/CTAs) to the FDA and International Agencies

The primary channel here is the formal submission package that allows clinical trials to start. Ovid Therapeutics Inc. is actively engaging with regulators to move its pipeline forward.

• Ovid Therapeutics Inc. is in the process of seeking scientific advice with regulators across multiple regions regarding OV329.
• For OV4071, the first oral KCC2 direct activator, IND-enabling studies are completing, with plans to submit for regulatory clearance in Q1 2026.
• The anticipated initiation of a Phase 2a patient study for OV329 in drug-resistant epilepsies is set for Q1 2026.
• The potential initiation of a proof-of-concept trial for OV4071 is targeted for Q2 2026.

Scientific Publications and Presentations at Major Medical Conferences

Scientific validation through peer-reviewed data and conference presentations is a critical channel for establishing credibility and attracting partners. You see this activity spiking around data readouts.

• Ovid Therapeutics Inc. announced positive topline results from its Phase 1 study of OV329 on October 3, 2025.
• Topline results from the OV329 Phase 1 safety, tolerability and biomarker study were expected in Q3 2025.
• OV329 Phase 1 results were selected for a late-breaking poster presentation at the 2025 American Epilepsy Society (AES) annual meeting.
• Ovid Therapeutics Inc. hosted an investor and media event on June 12, 2025, focusing on biomarkers in epilepsy and the OV329 program.

Licensing and Collaboration Agreements with Pharmaceutical Partners

These agreements are dual-purpose channels: they validate the science and provide non-dilutive capital. The monetization of existing assets is a key part of the current funding strategy.

Ovid Therapeutics Inc. has several key arrangements that serve as channels for value realization:

Partner/Agreement Type	Key Financial/Status Detail	Date/Period
Immedica Pharma AB (Royalty Sale)	Sale of worldwide ganaxolone royalty rights for $7.0 million	June 2025
Royalty Agreements (Revenue)	Revenue of $6.3 million for Q2 2025	Q2 2025
Royalty Agreements (Revenue)	Revenue of $132,000 for Q3 2025	Q3 2025
Takeda (Soticlestat)	Upfront payment of $196.0 million received	Prior to 2025
Takeda (Soticlestat)	Eligible for up to an additional $660.0 million in milestones	Ongoing
Takeda (Soticlestat)	Tiered royalties up to 20 percent on net sales	If approved
Graviton (ROCK2 Inhibitors)	Collaboration and license agreement for development through Phase 2 trials	April 2023

Still, the company is actively advancing multiple oral and injectable KCC2 activator programs selected from its proprietary library, which sets the stage for future deals.

Investor Communications via SEC Filings and Earnings Calls

Transparency with the investment community is managed through required filings and scheduled calls. These communications channel financial health and pipeline progress directly to shareholders.

Here are some key figures from recent investor communications:

• Ovid Therapeutics Inc. announced a PIPE financing on October 3, 2025, for up to $175 million in gross proceeds.
• The initial closing of the PIPE financing was approximately $81 million.
• Shares of common stock outstanding as of August 8, 2025, were 71,109,514.
• Cash, cash equivalents and marketable securities totaled $38.3 million as of June 30, 2025.
• Cash, cash equivalents and marketable securities totaled $25.6 million as of September 30, 2025.
• The post-PIPE financing cash runway is expected to support operations into 2H 2028.
• The net loss for the third quarter ended September 30, 2025, was $12.2 million, or basic and diluted net loss per share of $0.17.
• SEC filings are current through November 12, 2025.

Finance: draft 13-week cash view by Friday.

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Customer Segments

You're looking at Ovid Therapeutics Inc. (OVID) as of late 2025, and the focus for customer acquisition is squarely on patients with significant, often refractory, central nervous system (CNS) conditions. The company's ability to pursue these segments is underpinned by recent capital, specifically the up to $175 million in gross proceeds from a Private Investment in Public Equity (PIPE) financing announced in October 2025, with an initial closing of approximately $81 million, which management stated extends the cash runway into the 2H 2028.

The primary patient groups Ovid Therapeutics Inc. is targeting are defined by the unmet need addressed by their pipeline assets, which modulate neuronal hyperexcitability.

• - Patients with drug-resistant focal onset seizures (DREs).
• - Patients with psychosis associated with Parkinson's disease and Lewy body dementia.
• - Patients with other neurological and neuropsychiatric conditions driven by neural hyperexcitability.
• - Pharmaceutical companies seeking novel CNS assets for regional rights.

For the drug-resistant epilepsies segment, Ovid Therapeutics Inc. is advancing OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor. This patient group represents a substantial need, as an estimated 30% of epilepsy patients suffer from drug-resistant epilepsy. The focal seizures segment held the largest market share of 51% in the Epilepsy Drug Market in 2024. The company is planning the initiation of a Phase 2a patient study for OV329 in these drug-resistant epilepsies as early as Q1 2026 or Q2 2026.

The second major patient population centers around conditions driven by neuronal imbalance, specifically psychosis associated with Parkinson's disease and Lewy body dementia. This is being addressed via the KCC2 direct activator portfolio. Ovid Therapeutics Inc. projects the initiation of Phase 1b studies for OV4071, the oral KCC2 direct activator, in this indication around Q3 2026.

The broader category of other neurological and neuropsychiatric conditions is served by the entire KCC2 direct activator library, which aims to restore inhibitory tone in the brain. Key milestones here include the anticipated topline findings from the Phase 1 study of OV350 (Intravenous KCC2 Direct Activator) in Q4 2025. The company's focus on these CNS disorders is supported by recent asset monetization; for instance, a $7.0 million royalty monetization agreement for ganaxolone was signed with Immedica Pharma AB in June 2025.

The fourth segment involves other biopharma entities, which Ovid Therapeutics Inc. engages with for non-core asset monetization or potential regional rights deals. The royalty and licensing revenue for the nine months ended September 30, 2025, totaled $6.5 million, primarily stemming from an agreement with Takeda Pharmaceutical Company Limited. The company's market capitalization as of early October 2025 was approximately $116.62 million.

Here's a quick look at how the pipeline assets map to these customer-defining indications and the near-term data catalysts you should watch for:

Pipeline Asset	Mechanism/Class	Primary Target Customer Segment Indication	Key Near-Term Data Milestone (as of late 2025)
OV329	Next-generation GABA-AT inhibitor	Drug-resistant focal onset seizures (DREs)	Phase 1 results presented at AES 2025 meeting; Phase 2a initiation planned for Q1/Q2 2026.
OV350	KCC2 Direct Activator (IV)	CNS disorders driven by neuronal hyperexcitability	Phase 1 topline findings expected in Q4 2025.
OV4071	First-ever Oral KCC2 Direct Activator	Psychosis associated with Parkinson's/Lewy Body Dementia; other CNS disorders	First-in-human studies anticipated in Q2 2026; Phase 1b for psychosis projected for Q3 2026 start.

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Cost Structure

You're looking at the cost side of Ovid Therapeutics Inc. (OVID) as of late 2025, which is heavily weighted toward advancing its pipeline while managing a leaner operational footprint following prior restructuring. The primary cost drivers are the expenses tied directly to drug development and the overhead required to run a public, clinical-stage biopharma company.

The third quarter of 2025 (Q3 2025) financial results show a clear focus on R&D, though overall operating expenses were managed down year-over-year. Here's the quick math on the core operating costs for that quarter:

Cost Category	Q3 2025 Amount	Context/Driver
Research and Development (R&D) expenses	$5.9 million	Down from $7.9 million in Q3 2024, reflecting streamlined operations, including the pause of the OV888 (GV101) program.
General and Administrative (G&A) expenses	$6.8 million	Up from $5.5 million in Q3 2024, driven by specific non-routine costs.
Total Operating Expenses	$12.7 million	Down from $13.4 million in Q3 2024.

The structure of these costs reflects the company's current stage. You'll see that the G&A increase in Q3 2025, reaching $6.8 million, was specifically attributed to certain non-routine expenditures.

• Costs associated with maintaining and defending intellectual property: Ovid Therapeutics Inc. completed a strategic monetization of its ganaxolone asset in June 2025, selling worldwide royalty rights and licensing for $7.0 million. This deal included the transfer of the associated global ganaxolone intellectual property, with the buyer, Immedica Pharma AB, assuming responsibility for associated patent maintenance and prosecution costs. This move allowed Ovid Therapeutics Inc. to focus capital on its wholly owned pipeline and shed those specific IP upkeep expenses.
• Clinical trial costs and manufacturing of drug candidates: While specific Q3 2025 dollar amounts for clinical trial execution and drug candidate manufacturing aren't explicitly broken out separately from the R&D total of $5.9 million, the primary uses of capital are known to include third-party clinical research. The R&D spend supports active programs like the OV329 Phase 1 trial (with topline results in Q3 2025) and the OV350 Phase 1 study (results expected in Q4 2025).
• Compensation and professional fees, including non-routine business development fees: General and Administrative expenses primarily consist of employee-related costs, such as salaries, benefits, and stock-based compensation for executive and support functions. The increase in G&A to $6.8 million in Q3 2025 compared to the prior year was explicitly driven by non-routine business development professional fees. Other standard G&A costs include professional fees for auditing, tax, and legal services for operating as a public company.

Ovid Therapeutics Inc. (OVID) - Canvas Business Model: Revenue Streams

You're looking at how Ovid Therapeutics Inc. (OVID) is bringing in cash as of late 2025. For a company deep in clinical development, the revenue mix is often lumpy, relying on non-operational sources as much as product-adjacent income. Honestly, it's about bridging the gap until a wholly-owned asset gets across the finish line.

The core, recurring revenue stream is definitely tied to past deals. We saw royalty and licensing revenue totaling $6.5 million for the first nine months of 2025. That's a solid step up from the $0.5 million seen in the same nine-month period in 2024. To be fair, the third quarter itself was light on this front, bringing in only $0.1 million or $132,000 for the three months ending September 30, 2025. Still, that nine-month figure shows the importance of those existing agreements.

Ovid Therapeutics Inc. has also been strategic about monetizing non-core assets to bolster its balance sheet. The most recent, significant example was the sale of its future royalty rights for ganaxolone outside of China. This transaction, completed in June 2025, brought in proceeds of $7.0 million in cash from Immedica Pharma AB. This was a non-dilutive capital infusion, letting Ovid Therapeutics Inc. focus its internal capital on its wholly-owned pipeline, like OV329 and the KCC2 activators.

Here's a quick look at the key financial components feeding into the top line and capital structure as of late 2025:

Revenue/Financing Component	Amount/Value	Period/Date	Source Type
Royalty and Licensing Revenue (YTD)	$6.5 million	First nine months of 2025
Ganaxolone Royalty Sale Proceeds	$7.0 million	June 2025
Gross Proceeds from Private Placement	Up to $175 million	October 2025
Initial Gross Proceeds from Private Placement	Approximately $81 million	October 2025
Expected Cash Runway Funded Through	2028	Post-October 2025 Financing

Beyond operational revenue, the most impactful financial event for Ovid Therapeutics Inc.'s near-term runway was the equity financing. You saw the pricing of a Private Investment in Public Equity (PIPE) financing in October 2025, expected to bring in gross proceeds of up to $175 million. This deal was structured with an initial closing expected around October 6, 2025, yielding approximately $81 million before fees.

This capital infusion is defintely a game-changer for the business model, as it's intended to work alongside existing cash to fund the operating plan into 2028. This means Ovid Therapeutics Inc. has the financial backing to pursue key clinical catalysts without immediate pressure for further dilutive financing. The revenue streams, therefore, are a mix of:

• - Royalty and licensing revenue, totaling $6.5 million for the first nine months of 2025.
• - Upfront and milestone payments from strategic collaborations, which contribute to the overall licensing revenue.
• - Proceeds from the sale of non-core assets, like the $7.0 million ganaxolone royalty sale in June 2025.
• - Equity financing, including the October 2025 private placement of up to $175 million gross proceeds.